InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx N.V. announced new in vitro data showing that izicopan, their oral C5a receptor inhibitor, does not cause time-dependent inhibition of CYP3A4 enzyme, indicating a low risk for drug-drug interactions and liver toxicity. These results support izicopan’s differentiated safety and pharmacological profile, reinforcing its potential as a best-in-…